Background: Our purpose was to evaluate the prognostic impact of pathologically confirmed esophageal adenosquamous carcinoma (ASC) and its association with HER2 status and clinicopathologic characteristics.
sophageal carcinoma mostly comprises of 2 distinct histopathologic entities: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). Pure EAC typically originates from the distal esophagus or gastroesophageal junction (GEJ) preceded by a premalignant inflammatory condition called Barrett's metaplasia. EAC incidence has increased in Western countries, and major risk factors are gastroesophageal reflux and obesity. 1 By contrast, ESCC typically originates from the midesophagus or proximal esophagus, and its incidence has stabilized in the last 30 years with ESCC now far less common in the United States than EAC. Smoking, alcohol, low intake of fresh fruits and vegetables, low socioeconomic status have been implicated as risk factors for ESCC. 2 ESCCs have been reported in large surgical series to have a worse prognosis than EACs. 3 A recent advance in the treatment of EAC was the validation of human epidermal growth factor receptor 2 (HER2/ERBB2) as a therapeutic target in esophagogastric adenocarcinoma. 4 HER2 is a transmembrane tyrosine kinase receptor involved in controlling cell growth, survival, differentiation, and migration, and its expression/amplification has been detected in~15% of EACs as we 5, 6 and others 7 have shown. Its frequency appears to be less frequent in ESCCs. 8, 9 Adenosquamous carcinomas (ASCs) of the esophagus are uncommon tumors (0.37% to 1% of esophageal carcinomas) in which the pathologic features of both adenocarcinoma and squamous cell carcinoma reside within the same tumor. [10] [11] [12] [13] The prognostic impact, clinicopathologic and molecular characteristics of esophageal ASC are poorly understood. Barriers to further study include the lack of large cohorts of EAC with robust survival and clinicopathologic data. Here we examined the frequency, histologic characteristics, and survival of esophageal ASC in a large cohort of previously untreated patients who underwent surgical resection of their EAC. To better understand the pathogenesis of ASC as compared with EAC, we also compared ASCs and EACs in relation to smoking, BMI, and HER2 expression/amplification.
METHODS

Study Population
In the current study we analyzed data from the Mayo Esophageal Cancer Outcome Database, which was previously 
Identification of ASC
Twenty cases of ASC were selected as diagnosed in the original pathology reports. The glass slides were then retrieved and reviewed by a gastrointestinal pathologist (T.-T.W) and the paraffin blocks pulled in order to cut fresh sections. The new sections were stained with antibodies against p63 and cytokeratin CK5/6 to identify the squamous cell carcinoma component. Stains for chromogranin and synaptophysin to exclude a neuroendocrine component were also performed. In this manner ASC was confirmed in 16 patients. Thirteen ASC had node-positive disease, and the percentage of squamous versus adenocarcinoma cells in both primary and nodes was evaluable in 9 patients. The correlation in the percentage of tumor cells staining positive for p63 and CK5/6 was very high (data not shown); data for p63 are shown.
HER2
HER2 expression by immunohistochemistry (IHC; HercepTest [Dako] ) and HER2 gene amplification by fluorescence in situ hybridization (PathVysion) were assessed using gastroesophageal-specific criteria, as previously described. 5, 6, 15 For IHC, each case was scored by 2 pathologists (T-T.W., W.R.S.), as follows: high (IHC3 + ), strong intensity in 10% or more of cancer cells; medium (IHC2 + ), weak-moderate intensity in ≥ 10%; low (IHC1 + ), faint intensity in ≥ 10%; absent (IHC0). A specimen with an HER2/CEP17 ratio of ≥ 2.0 in invasive cells was classified as HER2-amplified. HER2-positive was defined as IHC3+ or IHC2+ with gene amplification, consistent with guidelines. 15 
Statistical Analyses
Statistical significance of the results was determined by χ 2 . Agreement in the percentage of SCC in the primary versus nodes was determined using the intraclass correlation coefficient with values <0.40, 0.40 to 0.75, and > 0.75 considered poor, fair to good, and excellent, respectively. 16 Univariate analysis of survival was performed using the Kaplan-Meier method. Cox proportional hazards models were used to estimate the univariate and multivariate association between predictor variables and outcomes. Overall survival (OS) was calculated as the time from surgery to death from any cause. Disease-specific survival (DSS) was calculated as the time from surgery to death due to index cancer. Events beyond 5 years were censored. P < 0.05 was considered significant. Data were collected using REDCap electronic data capture tools and statistical analysis was performed using JMP (JMP Pro 10.0.0; SAS Institute Inc., 2012) and MedCalc (version 14.12.0) software. Table 1 shows the baseline characteristics of the study population (N = 796). All patient tumors contained adenocarcinoma, and ASC was confirmed in 16 patients. None of the 16 patients with ASC had been diagnosed with a second primary at the time of surgery. Neoadjuvant chemotherapy with concurrent radiotherapy, chemotherapy alone, or radiotherapy alone was administered in 7 patients (0.9%), 1 patient (0.1%), and 1 patient (0.1%), respectively; no patient with ASC received neoadjuvant therapy. Adjuvant chemotherapy with concurrent radiotherapy, chemotherapy alone, or radiotherapy alone was administered in 53 patients (7%), 28 patients (4%), and 26 patients (3%), respectively; among patients with ASC, 2 patients received RT alone and 2 patients received chemoradiation.
RESULTS
Study Population
ASC in Primary Tumor and Nodes
In most patients with ASC (93% [15/16] ) squamous and adenocarcinoma cells were closely intermingled within the same primary tumor, although in 1 tumor (7% [1/15]) 2 distinct subpopulations of squamous versus adenocarcinoma cells were identified (Fig. 1) . Across all ASC tumors, SCCs comprised a Figure 2 , paired regional nodes were examined in nine primary ASC cases with node-positive disease that was evaluable for ASC (22 nodes in total) (see the Methods section). SCC was identified in at least 1 node in most patients (78% [7/9] ), and in those nodes SCC comprised at least 10% of tumor cells. The percentage of squamous versus adenocarcinoma cells in the primary showed good agreement with the corresponding percentage in the nodes (intraclass correlation coefficient = 0.73; 95% confidence interval (CI), 0.19-0.93), although discrepant cases were observed (eg, patients 3 to 5). For most patients with multiple nodes examined, the percentage of SCC cells in a node showed minimal variation between nodes.
Clinicopathologic Characteristics of ASC
Patients with esophageal ASC showed a statistically significant higher likelihood of being female (vs. male), having normal body mass index (vs. excess), and having a tumor that was HER2-negative (vs. HER2-positive), as compared with patients whose esophageal tumors showed adenocarcinoma only (Table 1) . Other characteristics, including the presence of adjacent intestinal metaplasia, were not noticeably different between ASC and adenocarcinoma-only patients.
ASC and Patient Survival
Median follow-up duration for surviving patients was 12.8 years. In univariate analysis ASC (vs. adenocarcinoma only) was associated with shorter DSS (5-year DSS rate = 6% vs. 34%, respectively; P < 0.0001 log-rank test) and OS (5-year OS rate = 6% vs. 31%, respectively; P = 0.0001 log-rank test) (Table S1, number of malignant nodes, and tumor grade were also associated with worse survival, supporting the generalizability of our cohort ( 
Discussion
To our knowledge, we report the first data on the prognostic impact of pathologically confirmed ASC in a large cohort of EAC in association with HER2 status and major risk factors. We found that ASCs comprised 2% of nonmetastatic esophageal/GEJ adenocarcinomas, and this rare histologic subtype was associated with a statistically significant > 2-fold worsening of DSS and OS after adjustment for covariates. In addition, we found that patients with ASC were statistically significantly more likely to be female, to have normal weight, and to harbor HER2-negative tumors, as compared with patients with EAC only. Together, these data indicate that ASC is a distinct aggressive subtype of EAC that warrants further investigation. Close intermingling of SCC and adenocarcinoma cells was observed in most primary esophageal ASCs, consistent with prior pathologic descriptions of ASCs in ESCC populations. 13, 17 The percentage of squamous versus adenocarcinoma cells in the primary showed good agreement with the corresponding percentage in paired nodes, with minimal internodal variation in the same patient, suggesting the intratumor heterogeneity of the primary ASC is generally recapitulated in metastatic lesions, although discrepancies between primary and node were also observed. Although the precise molecular characterization of this heterogeneity remains to be elucidated, it is increasingly accepted that clonal diversity in primary cancers may increase the risk of subsequent progression due to a broader assortment of subclones which allow for the selection and rapid progression of specific tumor subclones. 18 Consistent with the theoretically greater tumor aggressiveness conferred by intratumor heterogeneity, we found that patients with esophageal ASC had a significantly worse survival compared with those with adenocarcinoma only, even after adjustment for known prognostic variables. Our data are supported by 2 recent reports from population-based studies in the United States which found that esophageal ASCs are associated with worse OS as compared with EAC only. 10, 11 Advantages of the current study over prior reports include the expert pathologic confirmation of ASC, as well as the availability of data on treatment, BMI, smoking, and HER2 status. Interestingly, multiple prior studies have determined that the prognosis of esophageal ASCs were not significantly different from ESCCs. 10, 11, 13, 17, 19, 20 50 50
Patient
Primary Tumor (%) Regional malignant nodes (%)
Squamous cell carcinoma Adenocarcinoma Because of the low frequency of esophageal ASC, its clinicopathologic features are not well established. In our study patients with esophageal ASCs did not have significant differences from patients with EAC only in terms of smoking history, depth of tumor invasion, pathologic tumor grade, or the number of malignant nodes. However, patients with esophageal ASC (vs. EAC only) were less likely to have excess BMI, which is a known risk factor for EAC, but not ESCC. 21 In addition, no ASC demonstrated HER2 protein expression or gene amplification, in contrast to 17% of EAC-only tumors. Interestingly, esophageal ASCs did not show a significant difference from pure EACs with regard to their tumor location or the presence of adjacent Barrett's metaplasia, suggesting that esophageal ASC may be as likely to arise from Barret's as pure EAC. Our finding is consistent with data from rat models with surgically induced gastroduodenal reflux which have shown that ASCs arise in esophageal mucosa characterized by chronic squamous esophagitis 22 and glandular metaplasia, 23 suggesting that alkaline reflux esophagitis contributes to the genesis of not only EAC, but also ASC. 22 Esophageal or gastric ASCs are believed to develop from an unidentified common progenitor cell in some cases 24, 25 or through collision of 2 individual tumors in others. 26 Preliminary data indicate that EAC and ESCC components of esophageal ASC tumors share patterns of allelic loss at multiple chromosomal locations, TP53 mutation, and/or aberrant expression of p53, p16, and RB in some tumors, [27] [28] [29] whereas other esophageal ASC tumors exhibit significantly divergent alterations in microsatellites and beta-catenin and EGFR expression. 28, 30 In lung xenograft models, recent data suggest that ASCs originate from cancer stem-like cells that differentiate to multilineage structures with branching lung morphology expressing bronchial, alveolar, and neuroendocrine markers in vitro. Our findings provide rationale for examining esophageal ASC as a distinct entity in ongoing and future comprehensive molecular characterizations.
Strengths of our study include the large size and extensive clinicopathologic annotation of our cohort, knowledge of treatment received, and long duration of survival follow-up. Novel clinicopathologic annotations include BMI, adjacent Barrett's, smoking history, and HER2 expression and amplification using modern disease-specific methods. In addition, unlike prior studies, 10, 13, 17, 19, 20 the presence of ASC was confirmed by expert pathologic examination including the use of new immunostains. Limitations of our study include the retrospective nature of data collection and the relatively small number of ASC cases.
In conclusion, our study identifies esophageal ASC as a rare aggressive HER2-negative subtype with divergent clinicopathologic characteristics from pure EAC, highlighting the importance of further elucidating the molecular landscape of ASC.
